Toll Free: 1-888-928-9744

Pieris AG - Product Pipeline Review - 2014

Published: Oct, 2014 | Pages: 38 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Pieris AG - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Pieris AG - Product Pipeline Review - 2014', provides an overview of the Pieris AG's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Pieris AG's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Pieris AG including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Pieris AG's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Pieris AG's pipeline products

Reasons to buy

- Evaluate Pieris AG's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Pieris AG in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Pieris AG's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Pieris AG and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Pieris AG
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Pieris AG and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Pieris AG Snapshot 5
Pieris AG Overview 5
Key Information 5
Key Facts 5
Pieris AG - Research and Development Overview 6
Key Therapeutic Areas 6
Pieris AG - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Pipeline Products - Out-Licensed Products 11
Out-Licensed Products/Combination Treatment Modalities 12
Pieris AG - Pipeline Products Glance 13
Pieris AG - Clinical Stage Pipeline Products 13
Phase I Products/Combination Treatment Modalities 13
Pieris AG - Early Stage Pipeline Products 14
Preclinical Products/Combination Treatment Modalities 14
Discovery Products/Combination Treatment Modalities 15
Pieris AG - Drug Profiles 16
PRS-050 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
PRS-080 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
PRS-060 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
PRS-110 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
PRS-NN 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
Recombinant Protein 1 for Undisclosed Indication 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
Recombinant Protein 2 for Undisclosed Indication 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
Recombinant Proteins for Imuunology and Cancer 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
Recombinant Proteins for Undisclosed Indication 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
PRS-190 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Recombinant Protein for Ophthalmology 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Recombinant Proteins 3 for Undisclosed Indication 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Recombinant Proteins for Immuno-Oncology Diseases 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Pieris AG - Pipeline Analysis 29
Pieris AG - Pipeline Products by Target 29
Pieris AG - Pipeline Products by Route of Administration 30
Pieris AG - Pipeline Products by Molecule Type 31
Pieris AG - Pipeline Products by Mechanism of Action 32
Pieris AG - Recent Pipeline Updates 33
Pieris AG - Dormant Projects 35
Pieris AG - Locations And Subsidiaries 36
Head Office 36
Appendix 37
Methodology 37
Coverage 37
Secondary Research 37
Primary Research 37
Expert Panel Validation 37
Contact Us 38
Disclaimer 38
List of Tables
Pieris AG, Key Information 5
Pieris AG, Key Facts 5
Pieris AG - Pipeline by Indication, 2014 8
Pieris AG - Pipeline by Stage of Development, 2014 9
Pieris AG - Monotherapy Products in Pipeline, 2014 10
Pieris AG - Out-Licensed Products in Pipeline, 2014 11
Pieris AG - Out-Licensed Products/ Combination Treatment Modalities, 2014 12
Pieris AG - Phase I, 2014 13
Pieris AG - Preclinical, 2014 14
Pieris AG - Discovery, 2014 15
Pieris AG - Pipeline by Target, 2014 29
Pieris AG - Pipeline by Route of Administration, 2014 30
Pieris AG - Pipeline by Molecule Type, 2014 31
Pieris AG - Pipeline Products by Mechanism of Action, 2014 32
Pieris AG - Recent Pipeline Updates, 2014 33
Pieris AG - Dormant Developmental Projects,2014 35 



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $1500
Multi User - US $3000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify